Pamela Ingalls

Pamela Ingalls supports the National Institute of Allergy and Infectious Diseases (NIAID) in executing critical procurement initiatives aligned with the agency’s mission to advance biomedical research against infectious, immunologic, and allergic threats. She manages acquisitions for high-containment laboratory infrastructure, diagnostic reagents, and specialized analytical instrumentation essential to biosafety and biocontainment operations. Her work directly enables the development and deployment of medical countermeasures, ensuring NIAID’s readiness to respond to emerging public health threats through timely and technically rigorous contracting. Ingalls maintains consistent procurement relationships with Quality Biological, Inc., a key supplier of biological reference materials and research reagents, and Genomic Labs Ltd., a provider of advanced genomic analysis capabilities. These partnerships reflect a focus on vendors with specialized expertise in biosafety-compliant manufacturing and high-complexity laboratory services. Her contracting approach emphasizes technical precision and regulatory compliance, prioritizing vendors capable of meeting stringent federal biosafety standards and quality control protocols for biological and diagnostic products. Her procurement portfolio reflects a strong preference for unrestricted competition, with 85.7% of awards issued under no set-aside authority, indicating a focus on technical capability over socioeconomic classifications. However, she consistently allocates 14.3% of awards to total small business set-asides under FAR 19.5, demonstrating a measured commitment to small business participation without compromising mission-critical requirements. Ingalls’ primary procurement focus lies in NAICS 334516 (Analytical Laboratory Instrument Manufacturing) and 325414 (Biological Product Manufacturing), reflecting her specialization in procuring high-performance lab equipment, purified biological agents, and in-vitro diagnostic substances. Her expertise spans the full lifecycle of research-grade materials—from raw chemical inputs to validated diagnostic kits—ensuring NIAID’s laboratories remain equipped with the most reliable, compliant, and cutting-edge tools for infectious disease research.